OTR3 is a leading biotechnology company
in a new branch of Regenerating Medicine:
Matrix Therapy
OTR3® is a biotechnology company founded by Professors Denis Barritault and Jean-Pierre Caruelle† from the University of Paris-East Créteil in 2000, laureates of the French national competition for the creation of the best innovative company. Known for their pioneering work on growth factors – the discovery of FGF, HARP/PTN – they invented the RGTA® Technology (ReGeneraTing Agents), a new therapeutic class in regenerative medicine.
The RGTA® Technology is patent protected worldwide.
OTR3® has currently one CE marked medical device CACIPLIQ20® on the market.
OTR3® is the recipient of a H2020 SME Instrument Phase 2 funding to develop a new therapeutic product for the treatment of ischemic stroke.
The goal of OTR3® is to continue exploring the potential of the RGTA® Technology, developing new indications and innovative healthcare products. Our expansion relies on extensive cutting-edge research and development that will allow us to bring to patients innovative therapeutic solutions that really make a difference.
OTR3® focuses on extending its portfolio to a wider range of new products, each based on RGTA® molecules tailored for the treatment of specific diseases.
OTR3® doesn’t sell directly its products to the patient. The commercialisation of our products is licensed out to a network of pharmaceutical companies throughout the world.
OTR3®‘s multidisciplinary team is fully dedicated to bringing new products that really matter to answer the need of patients.
A steering board, composed of recognised professionals, assists OTR3’s team providing scientific, business and strategic advice.
Management Team
Pr. Denis BARRITAULT
President
Dr Laurent PINCHARD
Chief Operating Officer
Stéphane BARRITAULT
Vice PresidentSteering Board
